Deal With Gilead For Anti-CD123 Bispecific Offers Breath Of Fresh Air For MacroGenics

 
• By Alaric DeArment
Gilead and MacroGenics announced a deal worth potentially more than $1.7bn focused on an anti-CD123 bispecific antibody • Source: Shutterstock

More from Deals

More from Business